Application
Fig1: Western blot analysis of NLRP3 on different lysates using anti-NLRP3 antibody at 1/1,000 dilution.
Positive control:
Lane1: Human lung
Lane2: Mouse thymus
Lane3: THP-1
Application
Fig2: ICC staining NLRP3 in A431 cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.
Application
Fig3: ICC staining NLRP3 in HepG2 cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.
Application
Fig4: ICC staining NLRP3 in LOVO cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.
Application
Fig5: Immunohistochemical analysis of paraffin-embedded human liver cancer tissue using anti-NLRP3 antibody. Counter stained with hematoxylin.
Application
Fig6: Immunohistochemical analysis of paraffin-embedded human colon cancer tissue using anti-NLRP3 antibody. Counter stained with hematoxylin.
Application
Fig7: Immunohistochemical analysis of paraffin-embedded human placenta tissue using anti-NLRP3 antibody. Counter stained with hematoxylin.
Application
Fig8: Immunohistochemical analysis of paraffin-embedded mouse brain tissue using anti-NLRP3 antibody. Counter stained with hematoxylin.
Application
Fig9: Immunohistochemical analysis of paraffin-embedded mouse kidney tissue using anti-NLRP3 antibody. Counter stained with hematoxylin.
Application
Fig10: Flow cytometric analysis of Jurkat cells with NLRP3 antibody at 1/100 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black). Alexa Fluor 488-conjugated goat anti-rabbit IgG was used as the secondary antibody.